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RUNNING TITLE: ROCK2 in skin differentiation & cancer  
 
KEY WORDS: carcinogenesis, inhibition, differentiation, CAFs, ECM 
Summary: Inducible ROCK2 elicits epidermal hyperplasia via AKT1/GSK3β/β-catenin and 
elevated NF-κB; however, despite MypT-associated rigidity and tenascin C+ve dermal fibroblasts, 
compensatory p53/p21 and accelerated differentiation appear to inhibit papillomatogenesis. 
 
ABSTRACT 
ROCK2 roles in epidermal differentiation and carcinogenesis have been investigated in mice 
expressing an RU486-inducible, 4HT-activated ROCK2 transgene (K14.creP/lslROCKer). 
RU486/4HT-mediated ROCKer activation induced epidermal hyperplasia similar to cutaneous 
oncogenic rasHa (HK1.ras); however ROCKer did not elicit papillomas. Instead, anomalous basal-
layer ROCKer expression corrupted normal ROCK2 roles underlying epidermal rigidity/stiffness 
and barrier maintanance, resulting in premature keratin K1, loricrin and filaggrin expression. Also, 
hyperproliferative/stress-associated keratin K6 was reduced; possibly reflecting altered ROCK2 
roles in epidermal rigidity and keratinocyte flexibility/migration during wound healing. Consistent 
with increased proliferation, K14.creP/lslROCKer hyperplasia displayed supra-basal-to-basal 
increases in activated p-AKT1, inactivated p-GSK3βser9 and membranous/nuclear β-catenin 
expression together with weak NFκB, which were absent in equivalent HK1.ras hyperplasia. 
Furthermore, ROCKer-mediated increases in epidermal rigidity via p-MypT inactivation/elevated 
MLC, coupled to anomalous β-catenin expression, induced tenascin C-positive dermal fibroblasts. 
Alongside an altered ECM, these latent tenascin C-positive dermal fibroblasts may become 
putative pre-cancer associated fibroblasts (pre-CAFs) and establish a susceptibility that 
subsequently contributes to tumour progression. However, anomalous differentiation was also 
accompanied by an immediate increase in basal-layer p53/p21 expression; suggesting that whilst 
ROCK2/AKT1/β-catenin activation increased keratinocyte proliferation resulting in hyperplasia, 
compensatory p53/p21 and accelerated differentiation helped inhibit papillomatogenesis.  
 
  
INTRODUCTION   
ROCK2, a major effector of cytoskeletal architecture, regulates cellular flexibility/tension to 
maintain tissue rigidity and cellular motility in response to wounding or disease (1-4). This is 
achieved through regulation of actomyosin contraction via phosphorylation of myosin 
regulatory light chains (p-MLC) and the myosin-binding subunit of the MLC phosphatase (p-
Mypt1) that subsequently interface with numerous signalling pathways (3,4). In skin this 
mechano-signalling system is an essential component that contributes to keratinocyte 
proliferation and differentiation to maintain epidermal homeostasis and barrier function (5-7). 
ROCK family members are also required for epidermal formation (7) and together with 
appropriate intermediate filament expression (8), influence keratinocyte proliferation, and 
differentiation in terms of rigidity and flexibility. For instance, deregulation of ROCK2-
mediated actomyosin-mediated cellular tension in cutaneous keratinocytes leads to collagen 
deposition and increased skin rigidity (6). Increased matrix density subsequently changes 
integrin clustering, alters focal adhesions and establishes a mechano-transduction feedback 
loop that influences keratinocyte proliferation via FAK-mediated, α6/β4 integrin signalling 
(9,10). In turn, altered focal adhesion signalling through FAK/AKT activation downregulate 
GSK3β to increase β-catenin expression; with corresponding consequences for epidermal 
proliferation, differentiation and disease (1-4,6). In determination of keratinocyte 
motility/flexibility, ROCK1 and ROCK2 have separate roles in regulation of focal adhesion 
turnover (5,9) whilst in wounding, ROCK2 expression effects the migrating edge of full 
thickness wounds and overexpression accelerates healing (2).   
 
In human carcinogenesis, failures in ROCK2 signalling resulting in increased actomyosin-
mediated cellular tension and collagen deposition gives a rigid ECM (3,6) that provides a 
matrix permissive for tumour progression (11,12). In response to increased tissue stiffness, 
additional anomalous Rho-ROCK/β-catenin signalling has paracrine effects on specific dermal 
cells that remodel novel collagen fibres or alter expression of specific ECM molecules (13-15). 
These modifications then provide the highways for invasion that are exploited by ROCK-
modified cells possessing inherent changes to their actomyosin cytoskeleton resulting in the 
mechano-transduction abilities necessary to change cell shape and alter motility (1,3,6,12-15). 
Thus, given the lack of successful anti-ras therapies, in being downstream of ras signalling 
(3,4), the Rho kinase family have become attractive targets for potential therapy (16,17).  
In transgenic mice, epidermal expression of inducible ROCK2 [K14.ROCKer] enhanced 
malignant conversion following two-stage DMBA/TPA chemical carcinogenesis manifest by 
increased tissue rigidity (6). Similarly, ROCKer activation co-operated with epidermal rasHa 
activation [HK1.ras] to induce malignant conversion via p53 loss, increased p-Mypt1 and 
tenascin C overexpression, which altered the ECM to facilitate invasion (18). 
HK1.ras/K14.ROCKer  mice also identified ROCKer-associated synergism with NF-κB and 
AKT1 overexpression in late-stage papillomatogenesis that aided conversion to malignancy; 
together with p21-associated inhibition of early malignant progression (18). Indeed, 
malignancy depended on continued ROCKer/p-AKT1/NF-κB activation, as 4HT-cessation 
caused tumour regression via intense p21 [not p53] expression that identified an antagonism 
between p21 and endogenous ROCK2, which also targeted AKT1/NF-κB activation (18-20). 
Nonetheless, despite ROCK2 being an effector of rasHa signalling, and a potent regulator of 
AKT/GSK3β/β-catenin/FAK axis etc, ROCKer expression alone failed to exhibit papillomas 
(6, 18).  
Therefore, to investigate potential mechanism(s) that inhibited ROCKer-mediated 
papillomatogenesis, ROCK2, p53, p21, AKT/GSK3β/β-catenin and NF-κB status were 
assessed, together with tenascin C, and results contrasted to hyperplasia produced in HK1.ras 
mice; a model that produces wound-dependent papillomas with 100 % penetrance (21). Three 
themes responded to mechanical stress induced by ROCKer expression in K14.creP/lslROCKer 
hyperplasia. Two underlie inhibition of papillomatogenesis involving  changes in 
differentiation marker expression [Keratins K1, K6α, loricrin, filaggrin] that highlight a 
premature/accelerated commitment to differentiation and alter keratinocyte flexibility/motility; 
and responses to deregulated AKT/GSK3β/β-catenin axis that induce compensatory p53/p21 
expression to inhibit papillomatogenesis. The third found appearance of dermal, tenascin C-
positive fibroblasts that maybe precursors of subsequent cancer-associated fibroblast 
populations [pre-CAFs] (13,14); suggesting ROCKer-altered dermal ECM established at an 
early stage may persist to provide a latent oncogenic susceptibility that subsequently 
contributes to malignant conversion. 
  
MATERIALS AND METHODS      
Transgenic genotypes and induction of phenotypes. 
CAGG-lsl-ROCKER mice express a 4HT-inducible ROCK2/estrogen receptor fusion transgene 
such that following cre activity, ROCKer is expressed from a ubiquitous CAGG promoter (22). 
To achieve epidermal-specific ROCKer expression, CAGG-lsl-ROCKer were crossed to mice 
expressing a keratin K14-driven cre fusion protein [K14.creP (23,24)], where following topical 
treatment with RU486, bi-genic K14.creP/lslROCKer cohorts expressed ROCKer protein in all 
epidermal layers and hair follicles. Mice expressing epidermal activated rasHa from a modified 
keratin-K1 promoter [HK1.ras] have been reported previously (21). Genotypes were identified 
by PCR employing primers: 
 
lslROCKer: 1 fwd 5-CGACCACTACCAGCAGAACA-3; 2  rev:5-GACGAACCAACTGCACTTCA-3  
K14creP: fwd 5-TCATTTGGAACGCCCACT; rev: 5-GATCCGAATAACTACCTGTTTTG-3 
HK1.ras fwd: 5-GGATCCGATGACAGAATACAAGC-3; rev:5-ATCGATCAGGACAGCACACTTGCA-3 
 
Epidermal-specific ROCKer expression was achieved by topical treatment of 
K14.creP/lslROCKer skin with 2.5ug RU486/3x15ul ethanol/week for 3 weeks [mefipristone, 
Sigma, Gillingham, UK], with controls receiving ethanol alone. ROCKer activation via the 
modified oestrogen receptor HBD [mERTM], which binds the non-physiological ligand, 4-
hydroxytamoxifen [4HT;Sigma], was achieved by thrice weekly treatments of 330ug 4-
HT/15ul ethanol delivered to the dorsal ear skin and back [1mg/mouse]. Control mice received 
vehicle alone. Each cohort comprised 10 male and 3 vehicle controls in repeat experiments, 
maintained for 12, 20 and 30 weeks to assess papillomatogenesis. The ROCK:ER fusion 
protein, in which the ROCK2 kinase domain has been inserted between GFP and the hormone-
binding domain of a mutated estrogen receptor [ER] has been used previously to conditionally-
activate ROCK signalling (25) [Figure 1]. In the absence of an estrogen-like ligand such as 
tamoxifen, kinase activity is undetectable, while ligand stimulation results in the 
phosphorylation of genuine ROCK substrates including regulatory myosin light chains [MLC], 
the myosin-binding subunit of the myosin phosphatase complex [MYPT1] and the LIM kinases 
LIMK1 and LIMK2. The absence of activity without ligand stimulation and conditional 
activation by tamoxifen allows for precise control of the timing, duration and localization of 
ROCK activation in cells and tissues (25). One caveat that should be acknowledged is that, 
although the ROCK:ER fusion protein has been validated against previously characterized 
ROCK substrates, the possibility exists that additional substrates might also be phosphorylated. 
All experiments adhered to UK regulations; PPL60/4318 licenced to DAG. 
 
 
Histology, immunofluorescence/immunohistochemistry and western analysis     
Skin biopsies were fixed in buffered formalin [24hrs @ 4oC] for H&E staining or snap-frozen 
in liquid nitrogen and stored [-70C]. For differentiation analysis via double-label 
immunofluorescence, following antigen retrieval [5 mins. boil/10mM sodium citrate], paraffin 
sections were incubated overnight [4oC] with: rabbit anti-K1, anti-K6, anti-loricrin, anti-
filaggrin [diluted 1:100 (Covance, Richmond, CA)] employing guinea-pig anti-K14 antibodies 
[1:400 (Fitzgerald, Acton, MA)] to delineate epidermis; and visualized by biotinylated-goat 
anti-guinea pig/Streptavidin-Texas Red [1:100/1:400) (Vector Labs)] or FITC-labeled anti-
rabbit IgG [diluted 1:100; (Jackson Labs West Grove, PA)]. Sections were analysed by 
immunofluorescence for expression of: p-AKT1 [1:100; (abcam #81283 Cambridge, UK; 
Santa Cruz p-AKT1/2/3 sc-7985-R)]; β-catenin [1:50 (abcam; 1:100 sc#1496-R)]. For BrdU 
labelling, mice were injected IP with 125 mg/kg 5-bromo-4-deoxyuridine [Sigma] 2 hours prior 
to biopsy. Following antigen retrieval, BrdU-labelled cells were identified by overnight 
incubation [40C] with FITC-conjugated anti-BrdU [1:5, (Becton Dickinson)]. Positive cells 
were counted form 3 separate areas 5 of different mice per cohort and mitotic index expressed 
as BrdU-labelled cells per mm of basement membrane. 
For immunohistochemical analysis, following antigen retrieval, paraffin sections were 
incubated overnight [40C] with: rabbit anti-p53 1:50; sc#6243 Santa Cruz, Autogen Bioclear, 
Wiltshire, UK) and confirmed by abcam (#131442 @1/50); anti-p21WAF (1:50; sc#397; 
confirmed by Proteintech #10355-1-AP (1:250); anti-ROCK2 (1:100; sc#5561), β-catenin 
(1:150;sc#1496-R), confirmed by abcam (1/50;#32572); anti-p-GSK3β (1:50;sc#11757); 
rabbit anti-phospho-Mypt1Thr696 (1:50; Millipore AbS45, Watford, UK); rabbit anti-tenascin C 
(1:50; Sigma #T2551); rabbit anti-NF-κB p65 (1:600; abcam #16502); total GSK3β (1:200, 
abcam #32391); and rabbit anti-GFP (1:50; Clonetech, Takara Bio Europe, Saint-Germain-en-
Laye, France) followed by HRP-conjugated goat anti-rabbit (1:100; Vector) and visualised by 
DAB+ staining (Dako, Amersham Biosciences, Little Chalfont, UK). Photomicrographs 
employed Axiovision image capture software [Zeiss Microscopes, Cambridge, UK]. 
Quantitative analysis of the images [averaged from 6 separate areas] was performed using 
ImageJ software [ImageJ version 1.46r; National Institute of Health, Bethesda. USA] and 
statistical analysis employed one-way anova with post-hoc testing using SPSS software 
[version 22.0, IBM Corporation]. For quantitation of dermal tenascin C+ve cells, counts were 
averaged from 10 micrographs, taken from analysis of 3 separate animals per 12 weeks cohort, 
and compared to untreated or RU486-alone controls and RU486/4HT-treated HK1.ras mice. 
Results are expressed as numbers of positive cells per 0.25mm skin and anova statistical 
analysis.  
For western analysis, primary keratinocytes were isolated from newborn epidermis and seeded 
at 5 x 106/60mm dish and cultured in fibroblast conditioned, DMEM/10% chelated 
FCS/0.05mM Ca2+ (26) for 4 days, with/without 5x10-9M RU486; or 4HT (1nM; Sigma); then 
maintained in low [0.05mM] calcium or high [0.12mM] calcium media with/without 4HT 
(1nM) for three days. Cell lysates were prepared in lysis buffer [1% SDS/50mM Tris pH7.5] 
containing Protease inhibitor P-8340 [1:100;Sigma] and for keratin westerns, following 
centrifugation, pellets were re-suspended in keratin extraction buffer [10mM Na-phosphate 
pH8.0/2mM MgCl2/1mM EDTA/2mM DTT] homogenized and centrifuged [13,000 
rpm/10mins]. Supernatants were added to 200ul 2x SDS gel-loading buffer [100mM Tris 
pH6.8/4% SDS/10% glycerol/200mM DTT/0.1% bromophenol blue] homogenized and stored 
at -200C. Protein concentration was determined by bicinchoninic assay [Sigma] and proteins 
separated by 10% SDS-page electrophoresis and western blot analysis performed employing 
antibodies to: rabbit anti-K1, anti-K6 [1:1000 in 12% BSA-PBS]; anti-ROCK1/2 (Millipore 
07-1458), anti-p-MLC2 (p-Ser19), and anti-tMLC [1:500; Cell Signalling Technology] and 
expression detected by Alexa-Fluor 680 (Thermo-Fisher Scientific) secondary antibody and 
infrared imaging (Li-Cor Odyssey). Quantitative image analysis employed ImageJ software 
[ImageJ version 1.46r; National Institute of Health, Bethesda. USA] and statistical analysis 
employed one-way anova [version 22.0, IBM Corporation]. 
  
RESULTS   
 
ROCKer activation induces epidermal hyperplasia without papillomatogenesis   
RU486/4HT-treated K14.creP/lslROCKer mice, expressing 4HT-activated ROCKer from a cre-
responsive CAGG promoter, displayed epidermal hyperplasia but lacked papillomas. ROCKer 
expression in K14.creP/lslROCKer epidermis and cultured keratinocytes was confirmed PCR 
and western analysis (Figure 1A, B and C); whilst phosphorylation of myosin light chain 
protein (p-MLC) confirmed 4HT-mediated ROCKer activation in proliferative (low Ca2+) and 
differentiating (high Ca2+ conditions (Figure 1C). In vivo, despite thrice-weekly 4HT 
treatments over 12, 20 or 30 weeks (n=10/cohort), no overt papillomas appeared (Figure 2A) 
and RU486/4HT-treated K14.creP/lslROCKer mice exhibited ear thickening with mild 
keratosis by weeks 8-10; which regressed if 4HT was withheld. Histological analysis of 
RU486/4HT-treated K14.creP/lslROCKer mice revealed mild epidermal hyperplasia compared 
to normal RU486-treated control skin (Figure 2B-D), consistent with GFP-tag expression 
(Figure 2E and F), that confirmed ROCKer expression, being absent in untreated controls 
(Figure 2G). ROCK2 protein analysis revealed elevated ROCK2/ROCKer expression in 
hyperplastic RU486/4HT-treated K14.creP/lslROCKer and normal RU486-treated 
K14.creP/lslROCKer (Figure 2H and I); whilst endogenous ROCK2 expression in wild type 
controls appeared mainly suprabasal (Figure 2J) consistent with roles in epidermal rigidity and 
barrier maintenance.  
 
Differentiation marker expression implies inhibitory accelerated/premature 
differentiation.  
Given ROCK is an effector of ras signalling (3), yet failed to elicit papillomas, effects of 
ROCKer expression on keratinocyte differentiation were investigated (Figure 3) and results 
contrasted to hyperplasia induced by rasHa activation (21). In vitro, western analysis showed 
activated ROCKer elicited anomalous expression of differentiation marker keratin K1 in 
proliferating keratinocytes cultured in low calcium (Figure 3:  left panel 1: L vs L+). 
Furthermore, hyperproliferative, wound associated keratin K6α, normally highly expressed in 
low calcium keratinocytes, was abnormally low in RU486/4HT-treated bi-genic 
K14.creP/lslROCKer keratinocytes (Figure 3, L vs L+) returning to normality in differentiated 
high Ca2+ media (Figure 3, H vs H+). Quantitation of expression levels [Supp. Data: Figure 
S1] confirmed significant increases in K1 expression (L+; *p<0.01) in K14.cre/lslROCKer vs. 
lslROCKer keratinocytes cultured in proliferative low calcium conditions, compared to normal 
cells suggesting an altered, early differentiation; in addition the novel, unique decrease in K6α 
expression (L+; **p<0.01) also suggests either an early differentiation response or may reflect 
ROCK2 roles on K6α in these culture conditions that mimic mechanisms associated with 
wounding.  
In vivo, immune fluorescence analysis of K1 and K6α expression (Figure 3 left panel: K1 A-
D; K6 E-H] were investigated alongside late-stage differentiation markers filaggrin and loricrin 
(Figure 3 right panel: filaggrin A-D; loricrin E-H) employing keratin K14 to delineate the 
epidermis. RU486/4HT-treated K14.creP/lslROCKer hyperplasia shows keratin K1 expression 
was mainly supra-basal (Figure 3 left panel: A and B), however the normally smooth transition 
from proliferative basal to post-mitotic, supra-basal keratinocyte was not ordered; with 
numerous K1+ve cells appearing in the expanded (K14+ve) basal-layers. This ragged transition 
from proliferative to differentiating keratinocytes contrasted with the ordered differentiation 
observed in either normal, RU486-treated K14.cre/lslROCKer controls or HK1.ras-activated 
hyperplasia (Figure 3 left panel: C and D). Of note, normally keratin K6α expression is 
restricted to hair follicles becoming strongly expressed under stressed or hyperproliferative 
(wound) conditions; however RU486/4HT-treated K14.creP/lslROCKer hyperplasia displayed 
reduced, patchy K6α expression (Figure 3 left panel: E and F) often localised to troughs of 
papillomatous (folded/convoluted) hyperplasia, which possibly reflect the altered epidermal 
rigidity/flexibility. In contrast, normal RU486-treated K14.cre/lslROCKer epidermis exhibited 
K6α in hair follicles; whilst RU486/4HT–treated HK1.ras hyperplasia expressed strong, 
uniform K6α (Figure 3 left panel: G and H).  
Further consistent with anomalous modification of ROCK2 roles in differentiation, 4HT-
treated/RU486-K14.cre/lslROCKer epidermis displayed elevated/premature expression of late–
stage markers loricrin and filaggrin. ROCKer activation resulted in persistent, elevated filaggrin 
expression; with premature staining appearing in supra-basal layers of increasing hyperplasia 
compared to controls (Figure 3: right panel A, D vs C). However, as HK1.ras hyperplasia 
increased, filaggrin expression reduced (Figure 3: right panel D). Similarly, ROCKer activation 
increased premature, supra-basal loricrin expression (Figure 3: right panel E and F); whereas 
HK1.ras hyperplasia exhibited loricrin expression confined to granular layers similar to normal 
(Figure 3: right panel G and H). This elevated, premature filaggrin/loricrin expression would 
thus contribute to the increased epidermal rigidity observed in ROCKer mice and strengthen 
roles for ROCK2 in maintaining barrier function.  
 
ROCKer hyperplasia displays elevated basal-layer β-catenin, GSK3β inactivation and 
AKT1 activation.  
 
Previous analysis of ROCK-activated epidermis revealed increased β-catenin expression 
associated with AKT-mediated GSK3β inactivation (6) thus given the lack of ROCKer-
mediated papillomatogenesis and increased differentiation responses, the β-
catenin/GSK3β/AKT signalling axis was investigated and again cell/tissue localisation 
contrasted to HK1.ras-induced hyperplasia. Analysis of β-catenin expression in 4HT/RU486-
treated K14.creP/lslROCKer epidermis demonstrated increased expression in areas of 4HT-
treated vs. untreated skin (Figure 4A-C). Over time, increasing ROCKer-mediated hyperplasia 
displayed elevated, membranous β-catenin expression in both basal and supra-basal epidermis 
(Figure 4C) with detectable cytoplasmic/nuclear expression in basal layer keratinocytes (Figure 
4D). In contrast, 4HT/RU486-treated HK1.ras retained a mainly membranous β-catenin profile 
in supra-basal keratinocytes (Figure 4E). Quantitation (via image J analysis) of treated vs 
untreated areas (Figure 4A and B) show a significant difference in expression levels (# 
p<0.0001; supplemental data: Figure S2); a result repeated in equivalent immunohistochemical 
analysis (supplemental data: Figure S3). In comparison to HK1.ras hyperplasia, β-catenin 
expression in 4HT/RU486-treated K14.creP/lslROCKer epidermis was again significantly 
increased (**p<0.0001); with suprabasal β-catenin expression in HK1.ras remaining similar to 
supra-basal, membranous β-catenin levels of normal epidermis.  
 
Similarly, early 4HT/RU486-treated K14.creP/lslROCKer epidermis (4wks) shows elevated p-
GSK3β expression in 4HT-treated vs. untreated ear skin (Figure 4G) which was maintained in 
older hyperplastic skin (12wks; Figure 4H) where elevated p-GSK3β parallels β-catenin 
expression in both proliferative basal and differentiated supra-basal layers (Figure 4I vs 4D). 
4HT/RU486-treated HK1.ras hyperplasia (4wks) displays a less intense, diffuse p-GSK3β 
profile that with time and increasing papillomatous hyperplasia (8-10wks) showed reduced 
basal-layer and increasingly supra-basal p-GSK3β expression; which again parallels β-catenin 
expression in HK1.ras hyperplasia (Figure 4J vs 4E). Image quantitation (supplemental data: 
Figure S4) of 4HT/RU486-treated K14.creP/lslROCKer ears demonstrated elevated p-GSK3β 
expression in the upper treated dorsal skin vs. lower untreated inner skin (Figure 4G) (#p<0.05 
RU/tam ROCK vs no tam ROCK) and was maintained over time compared to levels in HK1.ras 
epidermis at 4wks (*p<0.001) and 8wks (**p<0.001).  
Analysis of p-AKT1 shows that ROCKer-activation increased expression in 4HT/RU486-
treated basal layers compared to normal RU486-treated K14.creP/lslROCKer which possessed 
only sporadic, supra-basal p-AKT1+ve keratinocytes (Figure 4L and M vs. N). Normal, neonatal 
epidermis (~24hrs) with a naturally hyperplastic epidermis also exhibited elevated p-AKT1, 
but expression was restricted to supra-basal layers (Figure 4O). Older (12wks) 4HT/RU486-
treated K14.creP/lslROCKer epidermis retained elevated interfollicular p-AKT1, which 
paralleled β-catenin/p-GSK3β expression, suggesting ROCKer established a return to a more 
juvenile epidermal context, possibly as a consequence of β-catenin expression (27); although 
here p-AKT1 exhibited supra-basal expression also (Figure 4P); possibly due to compensatory 
p53/p21 expression (see below), which helped inhibit papillomatogenesis. In contrast, 
4HT/RU486-treated HK1.ras hyperplasia expressed lower, supra-basal p-AKT1 (Figure 4Q) 
that with time reduced further to give a sporadic, supra-basal p-AKT1 expression similar to 
normal interfollicular epidermis (Figure 4N); suggesting AKT1 activation becomes causal later 
in ras–driven carcinogenesis. Image quantitation (supplemental data: Figure S5) shows 
4HT/RU486-treated K14.creP/lslROCKer skins expressed significant increases in p-AKT1 
levels compared to untreated areas (p<0.0001); including comparison to increased, suprabasal 
p-AKT1 expression exhibited by neonatal epidermis (p<0.001). Over time elevated suprabasal 
p-AKT1 expression was maintained in 4HT/RU486-treated K14.creP/lslROCKer epidermis 
compared to the low, sporadic levels observed in equivalent HK1.ras hyperplasia (p<0.0001). 
 
Elevated p-Mypt1 suggests changes in actomyosin-mediated contractility whilst cell-
specific tenascin-C highlights alterations in dermal ECM.   
Previously ROCKer activity altered ROCK2 signalling and increased phosphorylation of  
myosin-binding subunit of MLC phosphatase complex 1 (Mypt1) to inactivate MLC-
phosphatase activity; increase actomyosin-mediated cellular tension; collagen deposition in the 
dermal ECM and overall skin rigidity (6). Thus to both confirm ROCKer activity and indirectly 
the resultant epidermal rigidity, p-Mypt1 levels were investigated (Figure 5) alongside 
tenascin-C expression, an important ECM protein associated with tumour progression and 
ROCK signalling (15, 28) that also reflects changes in ECM. In 4HT-treated 
K14.creP/lslROCKer hyperplasia, ROCKer expression increased expression of phosphorylated 
Mypt1 (p-Mypt1; Figure 5A and B), consistent with increased tissue rigidity (6); whereas 
control, RU486-treated K14.creP/lslROCKer epidermis exhibited little detectable p-Mypt1 
(Figure 5D; *p<0.001 A and B vs D). HK1.ras hyperplasia also expressed low p-Mypt1 levels, 
confined to supra-basal layers (Figure 5C; **p<0.001 A and B vs C), and given this weak p-
Mypt1 yet uniform K6α (Figure 3), support the idea that ROCKer/p-Mypt1-mediated changes 
in keratinocyte motility/contractility via altered actinomyosin-mediated mechano-transduction 
contributed to the reduced, sporadic K6α profile.   
 
Tenascin-C analysis (Figures 5F-I) investigated whether early, pre-neoplastic stages exhibited 
changes in ECM (15, 28) that predispose to neoplasia, becoming causal later in malignant 
conversion/progression/tissue invasion; as observed in ROCKer/rasHa carcinogenesis (18). 
RU486-4HT-treated K14.creP/lslROCKer hyperplasia (Figure 5F) shows little epidermal 
tenascin-C but dermis exhibited numerous tenascin C+ve cells, absent in normal or RU486-
treated K14.creP/lslROCKer dermis (Figure 5G) and fewer in HK1.ras hyperplasia (Figure 5H). 
ROCKer-associated dermal tenascin C+ve cells also exhibited a diffuse peri-cellular halo 
suggesting expression in the local ECM; whereas in HK1.ras dermis, tenascin C+ve cells 
exhibited a sharp, membranous expression (Figures 5F-H). Quantitation of dermal tenascin 
C+ve cell numbers (Figure 5I) demonstrated K14.creP/lslROCKer  possessed approx. three-fold 
increase in tenascin C+ve cell numbers (19.43+/-2.21) (as did  4HT treated K14.ROCKer (18.40
+/-
1.43) (6,18); compared to HK1.ras-induced hyperplasia (7.09+/-1.43; p<0.05); with a five fold 
increase (p<0.01) over normal, RU486-treated K14.creP/lslROCKer (3.6+/-0.55) or RU486-
4HT-treated wild type skin (3.45+/-0.47). This tenascin-C expression may link ROCK
er/β-
catenin-associated increased collagen deposition (6) to effects of anomalous epidermal β-
catenin expression on specific dermal fibroblast populations (14); and also suggests that once 
laid down by tenascin C+ve cells, resultant ECM-associated changes coupled to tissue rigidity 
persists to aid/predispose to subsequent tumour progression (12).  
 
ROCKer hyperplasia displays increased p53/p21 expression responses that inhibit 
papillomatogenesis and limit NF-κB expression. 
Given these potent data on the AKT/GSK3β/β-catenin axis and the changes in ECM, the lack 
of papillomatogenesis compared to HK1.ras activation was unclear. Previously ROCKer 
cooperation with HK1.ras activation induced malignant conversion via p53 loss in papillomas 
and p21 loss following malignant conversion; where inhibition of early-stage malignant 
progression was also associated with a p21 antagonism to p-AKT1- and ROCKer-associated 
NF-κβ expression (18). Therefore, p53, p21 and NF-κB status were assessed in 
K14.creP/lslROCKer hyperplasia and contrasted to HK1.ras mice (Figure 6).  
Hyperplastic, RU486-4HT-treated K14.creP/lslROCKer shows elevated p53 expression 
appeared in both basal and supra-basal layers by 5-6 weeks (Figures 6A and B); whereas 
equivalent HK1.ras hyperplasia displays only sporadic p53 (Figure 6C)(**p<0.001; A and B 
vs C), as elevated p53 appears in overt papillomas to inhibit conversion (24). Untreated 
K14.creP/lslROCKer epidermis also displays sporadic p53 as specific keratinocytes complete 
the cell cycle (Figure 6D) (*p<0.001; A and B vs D). Similarly serial sections from 
RU486/4HT-treated K14.creP/lslROCKer demonstrated high p21 expression in all layers 
(Figures 6E and F); unlike HK1.ras hyperplasia which lacks p21 again until overt papillomas 
form (Figure 6G) )(**p<0.001; E and F vs G). Untreated, normal K14.creP/lslROCKer 
epidermis possessed occasional weak, basal and supra-basal p21 expression as cells commit to 
differentiation (Figure 6H) (*p<0.001; E and F vs H). Keratinocyte proliferation rates were 
assessed (Supplemental Figure S1) and expressed as BrdU-labelled cells per mm of basement 
membrane. Consistent with p53/p21 observations, 4HT-treated K14.creP/lslROCKer 
hyperplasia gave a mitotic index (12.1+/-2.6) approximately double that of normal epidermis 
(3.7+/-1.2) but less than HK1.ras epidermis (20.2
+/-6.1); hence a milder hyperplasia.  
Analysis of NF-κB in treated K14.creP/lslROCKer compared to HK1.ras hyperplasia (Figures 
6I-L) shows the beginnings of increased NF-κB expression in all layers compared to untreated 
K14.creP/lslROCKer ep (Figure 6I-K) (*p<0.05; I and J vs K) or RU486/4HT-treated HK1.ras 
hyperplasia (Figure 6l (**p<0.05; I and J vs L) which was similar to normal epidermis. Thus, 
in this pre-neoplastic context, p21/p53 responses coupled to increased/premature 
differentiation counter effects of AKT1/β-catenin signalling and/or ROCKer-associated NF-κB 
expression, to help inhibit ROCKer-mediated papillomatogenesis. 
  
DISCUSSION 
Inducible, ROCK2-mediated deregulation of the actinomyosin cytoskeleton in cutaneous 
keratinocytes resulted in epidermal hyperplasia with an altered differentiation profile, together 
with changes in dermal fibroblasts indicative of an altered ECM. Hyperplasia resulting from 
increased keratinocyte proliferation is consistent with ROCK/Rho family members being 
downstream effectors of ras signalling (3), and activation of AKT/GSK3β/β-catenin axis; 
which also contributed to a rigid skin (6). Here ROCKer/β-catenin-associated increases in 
dermal collagen deposition establishes a mechano-transduction feedback loop via FAK/AKT-
mediated, α6/β4 integrin signalling, that maintains hyperplasia and rigidity to lay down 
foundations for subsequent carcinogenesis (6,9-15, 27, 28). However in this pre-neoplastic 
context, unlike HK1.ras activation, responses to ROCKer-activated basal layer p-AKT1 and 
nuclear/membranous β-catenin immediately induced p53/p21 expression that limited 
keratinocyte proliferation and accelerated differentiation that, together with minimised NFκB 
expression, inhibited papillomatogenesis.  
 
These ROCKer-specific, premature/accelerated differentiation responses, echo (and may 
subvert) normal ROCK2 roles in epidermal homeostasis. In sync with appropriate intermediate 
filament (IF) expression, these roles are essential for embryonic epidermal barrier formation 
and to maintain tensile strength of differentiated epidermal layers in adult skin (7,8). Thus, 
normal epidermis shows ROCK2 expression in differentiated, supra-basal layers increases 
following induction of keratinocyte differentiation in vitro, together with targets p-MLC/p-
Myp (Figures 1,2 and 5) (5,9) consistent with a co-ordinated response between the IF and 
actinomyosin cytoskeleton networks as keratinocytes commit to differentiate (7,8). Hence, 
anomalous ROCKer activation and p-MLC/p-MypT expression in proliferative basal 
keratinocytes gave a resultant hyperplasia exhibiting an altered differentiation milieu (keratin 
K1, loricrin and filaggrin); while changes in epidermal flexibility/keratinocyte motility may 
alter expression of hyperproliferative/stress keratins e.g. K6α, that likely reflect roles in 
wounding (below). As K14.creP/lslROCKer mice exhibited anomalous K1 in keratinocytes 
cultured in low Ca2+ and premature increased keratin K1 expression in vivo, with a ragged 
appearance to the K1/K14 border; it suggests basal-layer ROCKer activation induced a 
premature commitment to differentiate, an idea also supported by increased/premature 
filaggrin and loricrin expression (Figure 3). The confused nature of the differentiation marker 
milieu may centre on anomalous ROCKer-activated p-AKT1 activation in basal layer 
keratinocytes (below); alongside β-catenin-mediated alteration of e.g. integrin signalling and 
focal adhesion turnover (6,9,11,29). Alternate signalling in HK1.ras hyperplasia support this 
idea, given the ordered nature of the K1/K14 border as keratinocytes committed to differentiate, 
and that reduced filaggrin/loricrin was paralleled by diminishing and increasingly supra-basal 
p-AKT1/β-catenin expression (Figure 4).  
Furthermore in K14.creP/lslROCKer epidermis, accelerated/premature expression of IF 
molecules that contribute to ROCKer/p-Mypt1-mediated changes in epidermal rigidity (6), may 
in turn inhibit papilloma formation. Previously, increased differentiation responses enforced 
by expression of K1 (or K10) inhibited ras-driven carcinogenesis (30,31). Moreover, cessation 
of 4HT-treatment in HK1.ras/K14.ROCKer carcinogenesis that demonstrated loss of ROCKer 
expression reduced tumour size also proceeded via a mechanism of increased K1-associated, 
differentiation (18). Moreover, it may be that premature K1 expression reflects epidermal 
responses to ROCKer-mediated p-AKT activation in basal layer keratinocytes. In normal adult 
epidermis, interfollicular p-AKT1 expression was sporadic and suprabasal, whereas in neonatal 
epidermis p-AKT1 expression is uniform and co-localised with supra-basal K1 (Figure 4). This 
feature maybe geared to counter potential threats to early barrier maintenance from e.g. p53-
mediated apoptosis whilst p53 completes DNA scrutiny in the naturally hyperproliferative 
basal-layer keratinocytes; and thus AKT1 gives time for keratinocytes to commit to terminal 
differentiation not apoptosis (24,32). Hence, ROCKer-mediated basal-layer p-AKT1 in adults 
signalled a premature commitment to differentiation manifest by increased, ragged K1 
expression that helps inhibit papillomatogenesis; whereas HK1.ras hyperplasia exhibits 
sporadic, supra-basal p-AKT1; and K1 expression is delayed, yet ordered.   
Another aspect of epidermal differentiation unique to K14.creP/lslROCKer hyperplasia, was 
the lack of keratin K6α expression, a hair follicle marker associated with hyperproliferative, 
stressed or wound conditions (8,33,34). Treated K14.creP/lslROCKer epidermis exhibited 
reduced/patchy K6α expression, often localised to troughs of papillomatous 
(folded/convoluted) hyperplasia, compared to the uniform strong expression typified by 
HK1.ras hyperplasia prior to papilloma formation. In vitro, strong K6α expression observed in 
normal, proliferative keratinocytes, was virtually absent in RU486/4HT-treated 
K14.creP/lslROCKer keratinocytes (Figure 3). These observations may reflect ROCK2 roles in 
epidermal rigidity/flexibility and those that regulate motility/flexibility at the cellular level 
following wounding. Both ROCK1 and ROCK 2 are necessary for migratory responses in 
wounding, consistent with the finding that epidermal ROCKer expression accelerates healing 
of cutaneous full thickness wounds (2,4,35). Thus, ROCKer-activated/p-MLC/p-Mypt1-
regulated changes coupled to premature expression of K1/loricrin/filaggrin (above) that 
increase epidermal rigidity, may combine to reduce K6α in attempts to maintain tissue 
flexibility. If correct, this idea partly explains the localisation of K6α expression in troughs of 
folded/papillomatous hyperplasia and is an idea supported by full-thickness wounding of 
K6α/β knockout mice that also display increased K1/K10 co-expression to increase tissue 
rigidity to counter cell fragility in a wounded skin (33,34).  
Further, at the cellular level reduced K6α expression (and partner keratin K16 (36)) may 
represent an intermediate state of rigidity/flexibility geared to help initiate keratinocyte 
proliferation early in wound healing (33). This would facilitate subsequent ROCK-associated 
keratinocyte migration (2,34,36); as suggested by analysis of cell migration observed at wound 
margins in K6α/β knockout mice that demonstrates F-actin expression at the leading edge (34), 
indicative of the localised ROCK1/2 roles in cell motility (2-4). These data highlight the 
balance between stress/wound-associated K6α/β/K16 (35,36) IFs and the ROCK-associated 
actinomyosin cytoskeleton in the cellular/tissue flexibility/motility necessary to maintain 
migration vs rigidity for epidermal homeostasis in wounding (2); where deregulation of this 
balance may facilitate the increased motility/rigidity observed in skin cancer (6,12,15,18). 
Indeed, as evidenced from in vitro interfollicular stem cell lineage studies (37), it may be that 
ROCK2 has a pivotal role in regulating the balance between proliferation and differentiation 
to maintain epidermal homeostasis, as suggested in the wound response [above]. This in vitro  
study [and reports referenced therein], shows that ROCK signalling is essential to stem cell 
population decisions to proliferate and maintain either a confluent, quiescent colony or an 
expanding one. In this model, as human stem cell keratinocytes cultured on feeder layers 
establish colonies that approach local confluence, ROCK2 kinase activities were instrumental 
in the decision to switch from an expansion phase, where proliferation dominates over 
differentiation, to one of balance where keratinocyte proliferation replaces only those cells 
committed to differentiation (37). Furthermore, in scratch assays that mimic wounding, 
ROCK2 signalling was also essential to reverse this decision and change from the balanced 
mode and return to the expanding phase (37). These data would be consistent with roles 
observed in cell migration (2,4,33-36) and with the findings in this transgenic skin model 
regarding anomalous, inducible basal layer ROCKer expression that clearly disturbs the 
respective balanced vs expansion proliferation modes. That this leads to an overall hyperplasia 
which also exhibits premature differentiation marker expression, further reflects the 
importance of ROCK2 signalling in the commitment to proliferate (37), differentiate (5) and 
the responses geared to enhanced wounding/cell migration (2) or threats to maintenance of the 
paramount barrier function (12).   
Thus, a surprising finding in this ROCKer model was the lack of spontaneous 
papillomatogenesis and this highlights the ability of tissues to inhibit early-stage 
carcinogenesis, particularly in skin evolved to constantly cope with environmental carcinogens. 
The data outlined above suggest an epidermis employs differentiation-specific responses to 
ROCKer-mediated p-AKT1/GSK3β/β-catenin deregulation to inhibit papilloma. In addition 
this axis appears to induced an immediate, elevated p53/p21 expression; a response absent in 
HK1.ras hyperplasia destined to produce papillomas. In this instance anomalous ROCKer-
mediated β-catenin/Wnt signalling may be a major facet that induced p53, as previously β-
catenin knockout blocked ROCKer phenotypes (6). Such compensatory p53 expression was 
observed previously in this model, alongside p-AKT-induced p21 expression (18, 24); whilst 
in colon carcinogenesis APCnull-mediated nuclear β-catenin induced transcriptionally active 
p53 (38-40). Further, ROCK signalling in focal adhesion turnover (9) shows FAK expression 
supresses Rho activity and ROCK2 compensates for FAK loss (10). Thus, it is noteworthy that 
FAK deletion also demonstrates p53-mediated induction of p21 (41) as observed for ROCK 
(19); that also links to β-catenin, as FAK overexpression is a necessary downstream event of 
APC/β-catenin/WNT signalling (29, 42), which presumably circumvents compensatory 
p53/p21 inhibition (24,29,39-42).  
 
Here, p53/p21 expression in K14.creP/lslROCKer hyperplasia successfully counters threats 
from membranous/nuclear β-catenin/p-AKT1 expression via a reduced proliferation rate;  
elevated p53-mediated protection against additional mutations and increased p21-associated 
differentiation responses (42); yet avoids excessive p53/p21 induced apoptosis due to 
continued p-AKT1/p53 antagonism that maintains the paramount barrier function (above) 
(25,32). Indeed older 4HT/RU486-treated K14.creP/lslROCKer epidermis retained the 
elevated, interfollicular p-AKT1 observed in neonates, suggesting ROCKer established a more 
juvenile epidermal context that initially paralleled β-catenin/p-GSK3β expression (27). 
However, with time, p-AKT1 expression became increasingly supra-basal; possibly as a 
consequence of p21 expression; now inhibiting the potential for p-AKT1-associated 
papillomatogenesis. Accordingly, HK1.ras hyperplasia displayed a sporadic, supra-basal p-
AKT1 expression profile paralleled by increasingly supra-basal β-catenin expression; 
suggesting that in ras-driven papillomatogenesis AKT1 appears causal at later stages (ms in 
prep). 
   
Another major pathway previously implicated in HK1.ras/K14.ROCKer carcinogenesis 
involved canonical NF-κB signalling (20,43-46) and linked ROCKer-associated NF-κB 
expression with the latter stages of malignant conversion and progression (18,20). NF-κB 
signalling has a long association with effecting inflammatory responses; yet transcriptional 
roles also regulate proliferation, apoptosis and cell migration (43). In K14.creP/lslROCKer 
hyperplasia, initial cross-talk between ROCKer and NF-κB signalling would contribute to 
increased proliferation (18); but increasing p21 (18,19) and p53 (18,44) apparently reduced 
NF-κB expression to weak, yet detectable levels. In this instance, p21 rather than p53 maybe 
the significant facet of ROCKer-specific NF-κB inhibition (19,45), as previously 
HK1.ras/K14.ROCKer carcinogenesis identified a distinct antagonism between p21 and NF-
κB; as regressing tumours following 4HT-cessation displayed intense, basal-layer p21 which 
restricted/returned NF-κB (and p-AKT1) to the supra-basal expression profile observed in 
papillomas (18). A result also consistent with liver carcinogenesis, where NEMO, a major NF-
kB regulator, requires p21 loss for NEMO-driven tumour progression (45,46); and 
HK1.ras/K14.ROCKer carcinogenesis where p21 loss allows ROCKer–mediated NF-κB to 
combine with unregulated p-AKT1 to achieve malignancy. These data strengthen links 
between ROCKer/NF-κB and also indirectly link NF-κβ signalling to stromal remodelling that 
predisposes to tumour progression via expression of ECM molecules, such as tenascin C (47).   
 
An altered stromal ECM is an essential factor for carcinogenesis, aiding tumour cell survival 
and providing the permissive environment for cellular invasion and tenascin C is one of the 
most relevant molecules mediating changes to the dermal ECM, reflecting both tumour 
aggression and metastatic potential (28). Tenascin C overexpression is already associated with 
activated Rho/Rock and MAP Kinase signalling (15,18), with links to NF-κβ roles in 
inflammation and deregulated apoptosis (47), that may protect initiating cancer stem cells 
leading to tumour relapse (48). Thus, in K14.creP/lslROCKer mice altered mechano-signalling 
via epidermal MLC/Mypt1 phosphorylation; coupled to ROCKer/β-catenin-associated 
deposition of collagen/fibrin, increases dermal ECM rigidity and one consequence apparently 
manifests as intense tenascin C expression in a specific sub-population of dermal fibroblasts.  
Moreover, these tenascin C+ve cells maybe precursors of cancer-associated fibroblasts 
(CAFs)(13), a sub-population of stromal cells that aid the invasion process by aligning collagen 
fibres to provide highways within the ECM for invading SCC cells (13,28,49). Indeed a 
predisposed, promoting role for such (pre-CAF) dermal cells is supported by the observation 
that in RDEB patients susceptible to SCC following injury (12), a population of wound-
associated myofibroblasts alters the rigidity of the dermal microenvironment via a mechanism 
of increased integrin/FAK/AKT signalling similar to that observed in ROCKer mice (6,12).  
 
CAFs share many similarities with such myofibroblasts and are thought to arise from healthy 
dermal cells subverted by the new microenvironment conditions (13,28,49), such as those laid 
down in a ROCKer dermis. Further, CAFs form anomalous adhesion junctions with invading 
SCC cells that triggers β-catenin recruitment and vinculin/α-catenin-dependent adhesion, 
establishing a feedback loop to increase rigidity of the tumour microenvironment that aids 
invasion (50). However, the mechanism by which normal fibroblasts evolve into CAFS is 
unclear; mainly due to the heterogeneity within the tumour microenvironment (13,28,49). 
Thus, it is noteworthy that anomalous, epidermal-specific β-catenin expression effects specific 
populations of dermal fibroblasts (14) and this suggests ROCKer-mediated β-catenin 
expression may begin their evolution into a pre-CAF phenotype. Nonetheless, whilst fully 
evolved CAFs are essential for tissue invasion, providing an invasive highway from re-aligned 
collagen fibres and helping to maintain cancer stem cells (48,51) such tenascin+ve (pre-CAF?) 
dermal fibroblasts appear unable to influence papillomatogenesis, in the absence of tumour 
promotion (6,12).  
 
Collectively these data show that the cellular potential to achieve even a benign tumour 
depends upon specific genetic mutations pitted against inherent abilities within the cell/tissue 
microenvironment that resist the modified oncogenic circuitry. In K14.creP/lslROCKer 
epidermis, papillomatogenesis awaits permissive events such as a constitutive promotion role 
currently under investigation; whereas a potent initiator such as HK1.ras expression or 
chemically-induced rasHa activation achieves papilloma and circumvents these p53/p21 
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Figure 1: Schematic of K14.creP/lslROCKer system and conformation of ROCKer activation. 
(A) K14 promoter drives expression of a cre recombinase-progesterone ligand binding domain 
(PLB) fusion protein (K14.creP) and following RU486 treatment, CREP ablates a loxP-flanked 
stop cassette to express ROCKer from the CAGG promoter (CAGGS-lslROCKer). (B) PCR 
analysis of RU486-treated K14.creP/lslROCKer skin identifies K14.creP (~600bp; lanes 1-3); 
primers 1/2 (arrows) identify the ablated stop codon band at ~500bp and full-length product (~ 
575bp) in untreated epidermis and non-epidermal tissue (lanes 1 and 2), untreated (lane 3*) or 
CAGGS-lslROCK2er alone DNA (ethanol/lane 4*; RU486/lane 5). (C) Conformation of 
ROCKer activation. Primary K14creP.lslROCKer keratinocytes cultured in RU486 under 
proliferative low (L: 0.05mM) or differentiating (H: 0.12mM) calcium concentrations, with or 
without 1nM 4HT (L+; H+) show ROCKer increases following 4HT-treatment. ROCK2 
activity determined by phospho-MLC expression, increases on induction of differentiation and 
increases further following additional 4HT-mediated ROCKer activation. Total MLC served as 
a loading control.  
 
Figure 2: Conformation of ROCKer expression in K14.creP/lslROCKer phenotypes.  
(A) 4HT/RU486-treated K14.creP/lslROCKer mice (20wks) exhibit mild keratosis but despite 
thrice-weekly treatments (up to 6 months), no papillomas appear. (B) 4HT/RU486-treated 
K14.creP/lslROCKer mice exhibit mild epidermal hyperplasia (12wks) compared to (C) normal 
RU486-alone control skin (20wks) that (D) increases over time (20wks) but remains 
hyperplastic. (E-G) GFP-tag analysis of K14.creP/lslROCKer skin confirmed ROCKer 
expression in (E) hyperplastic 4HT/RU486-treated and (F) normal RU486-alone skin, was 
absent in (G) untreated controls. (H-J) Analysis of ROCK2/ROCKer protein levels shows (H) 
hyperplastic K14.creP/lslROCKer epidermis exhibits elevated expression following 
4HT/RU486 alongside (I) RU486-alone controls; compared to lower, suprabasal expression in 
(J) normal epidermis (bars: B approx.80µm; C-J approx.40µm;E and  H approx. 30µm).  
 
Figure 3: Analysis of differentiation marker expression.  
Western analysis of Keratin K1/K6α expression: Primary K14creP.lslROCKer or control 
lslcagROCKer keratinocytes are cultured in low or high calcium media ((L= 0.05mM; H= 
0.12mM) containing RU486 (5nM) with/without 4HT (1nM; L+/H+). ROCKer activation 
induces anomalous K1 expression in low calcium medium, which was absent in untreated or 
4HT–treated lslROCKer controls (L+ versus L); with elevated K1 expression in high calcium 
similar to normal 4HT–treated lslROCKer controls keratinocytes. ROCKer activation also 
down-regulates K6α in hyperproliferative, low calcium K14creP.lslROCKer keratinocytes (L+) 
compared to normal4HT–treated lslROCKer controls. Total MLC served as a loading control. 
Expression level quantitation is given in Supplemental data: Figure S1.  
Left Panel: Immunefluorescence analysis of Keratin K1 (A-D) and K6α (E-H) expression 
(green), counterstained for K14 (red) to delineate epidermis/dermis. (A and B) 4HT/RU486-
treated K14.cre/lsl.ROCKer hyperplasia display a ragged/disordered, supra-basal K1 profile, as 
proliferative K14+ve-basal layer cells differentiate and transit into supra-basal keratinocytes. 
(C) None-4HT/ RU486-treated control K14.cre/lsl.ROCKer epidermis displays normal, supra-
basal K1; whilst (D) HK1.ras hyperplasia exhibits an ordered K1 pattern at the K1/K14 
transition border. (E) 4HT/RU486-treated K14.cre/lsl.ROCKer and (F) K14.ROCKer 
hyperplasia display patchy K6α expression compared to (G) normal epidermis with K6α 
restricted to hair follicles. (H) HK1.ras hyperplasia exhibits strong, uniform K6α (bars: E G 
and H, approx.120µm; A, D and F: approx.70-80µm; B and C: approx.40µm).  
Right Panel: Filaggrin (A-D) and loricrin (E-H) expression in 4HT/RU486-treated 
K14.cre/lsl.ROCKer. (A and B) Elevated filaggrin expression increases with increasing 
hyperplasia (12 and 30wks); showing (B) premature filaggrin detectable below the granular 
layer compared to (C) granular layer filaggrin in normal epidermis. (D) HK1.ras displays 
reduced filaggrin as hyperplasia increases. (E and F) Loricrin expression in treated 
K14.cre/lsl.ROCKer hyperplasia (@ 12 and 30wks) shows increased, premature expression 
becomes detectable in supra-basal layers. (G) Untreated K14.cre/lsl.ROCKer epidermis exhibits 
granular loricrin expression; whilst (H) HK1.ras hyperplasia expresses reduced, granular 
loricrin. (Bars: approx.70-80µm)  
 
Figure 4: Analysis of β-catenin, p-GSK3β and p-AKT1 expression.  
(A and B) β-catenin expression in K14.creP/lslROCKer epidermis (4-6wks) at the junction 
between RU486 alone (left) and 4HT/RU486-treatment (right) shows expression increases in 
4HT-treated areas (B: double-label vs K14 (red) counterstain). (C) Older 4HT/RU486-treated 
K14.creP/lslROCKer hyperplasia (10wks) shows elevated β-catenin in basal and supra-basal 
layer keratinocytes. (D) Higher magnification of K14.creP/lslROCKer epidermis (10wks) 
shows detectable cytoplasmic/nuclear β-catenin expression in basal layer keratinocytes 
compared to (E) HK1.ras hyperplasia (8wks) which exhibits less membranous basal-layer β-
catenin expression [green] with infrequent nuclear expression (For quantitation and 
immunohistochemical analysis, see supplemental data Figure S2 and S3). (G) p-GSK3β 
expression in (upper) 4HT-treated vs (lower) untreated K14.creP/lslROCKer ear skin shows 
stronger expression in 4HT-treated epidermis  becoming stronger and more uniform with time 
in (H) older (12wks) 4HT/RU486-treated K14.creP/lslROCKer hyperplasia. Higher 
magnification (I) shows 4HT/RU486-treated K14.creP/lslROCKer hyperplasia maintains 
elevated p-GSK3β expression in both basal and suprabasal layers; whereas (J) HK1.ras 
hyperplasia displays less p-GSK3β that weakens in basal layers by 8wks and becomes 
increasingly supra-basal; again in parallel to β-catenin. (For quantitation see supplemental 
Figure S4). (L and M) p-AKT1 analysis in 4HT/RU486-treated K14.creP/lslROCKer epidermis 
(4wks) shows elevated basal-layer expression compared to (N) sporadic, supra-basal p-AKT 
expression in normal adult skin; yet similar to (O) normal neonatal skin (24hrs) that exhibits 
uniform, supra-basal p-AKT1. (P) Older (12wks) 4HT/RU486-treated K14.creP/lslROCKer 
epidermis retains elevated p-AKT1, but with areas of supra-basal expression; similar to 
neonates. (Q) HK1.ras hyperplasia (4-5wks) displays supra-basal and increasingly sporadic 
areas of p-AKT1 (For quantitation: see supplemental Figure S5) (Bars:  G,H, and J approx. 
120µm;  A, C, P and  N  approx. 80µm;  B, E, I, O and Q approx. 50µm; Q,  D, L and M 
approx. 30µm). 
 
Figure 5: Analysis of p-Mypt1 and tenascin-C expression in K14.creP/lslROCKer  
(A) 4HT/RU486-treated K14.creP/lslROCKer epidermis at (12wks) shows ROCKer-activated p-
Mypt1 expression in all layers is (B) maintained over time (24wks) compared to (C) equivalent 
4HT/RU486-treated HK1.ras hyperplasia (**p< 0.001; A and B vs C)  or (D) control RU486-
treated K14.creP/lslROCKer epidermis (*p< 0.001; A and B vs D). (F) 4HT/RU486-treated 
K14.creP/lslROCKer skin shows little epidermal tenascin-C expression but numerous tenascin-
C+ve cells appear in reticular/papillary dermis, with a halo of diffuse ECM expression. (G) 
RU486-alone treated K14.creP/lslROCKer dermis exhibits sporadic tenascin-C+ve cells, whilst 
(H) HK1.ras dermis exhibits fewer tenascin-C+ve cells that lack diffuse, ECM expression. (I) 
Quantitation of dermal tenascin-C+ve cells (per 250µm skin; averaged from 30 micrographs)): 
4HT/RU486-treated K14.creP/lslROCKer  (19.43+/-2.21); K14.ROCKer (18.40
+/-1.43); HK1.ras-
induced hyperplasia (7.09+/-1.43); RU486-alone treated K14.creP/lslROCKer  (3.6
+/-0.55); non-
transgenic control skin (3.45+/-0.47) (bars: F approx. 160µm; H approx. 140µm; E 
approx.100µm; A and B approx.75µm; C,D and G approx.50µm).   
 
Figure 6: Analysis of p53, p21 and NF-κB expression in K14.creP/lslROCKer and HK1.ras 
hyperplasia. (A) 4HT/RU486-treated K14.creP/lslROCKer epidermis (6wks) shows elevated 
p53 expression in basal layer keratinocyte cytoplasm/nuclei, becoming (B) expressed in all 
layers (12wks). In comparison (C) HK1.ras hyperplasia (6wks) displays weak p53 in sporadic 
keratinocytes (**p< 0.001; A and B vs C); whist (D) untreated K14.creP/lslROCKer epidermis 
displays little detectable p53 (**p< 0.001; A and B vs D). (E and F) 4HT/RU486-treated 
K14.creP/lslROCKer epidermis (6wks) exhibits elevated basal-layer p21 in nuclei and 
cytoplasm, becoming uniform in all layers by 12 weeks. (G) HK1.ras hyperplasia (6wks) 
exhibits occasional, supra-basal p21 expression (**p<0.001; E&F vs G); similar to (H) RU486 
alone-treated K14.creP/lslROCKer epidermis (*p<0.001; E&F vs H). (I and J) 4HT/RU486-
treated epidermis shows low yet detectable NF-κB expression (12wks) in basal-layer 
keratinocytes compared to (K) 4HT/RU486-treated HK1.ras hyperplasia (**p<0.05; I and J vs 
K) or (L) normal RU486-treated K14.creP/lslROCKer epidermis that express little detectable 
NF-κB (*p<0.05; I & J vs L) (bars: D and H approx. 90-100µm; A and E: 80-90µm; B, C K 
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